CU23318A7 - Composiciones farmacã0/00uticas de la tizoxanida y nitazoxanida - Google Patents

Composiciones farmacã0/00uticas de la tizoxanida y nitazoxanida

Info

Publication number
CU23318A7
CU23318A7 CU20030074A CU20030074A CU23318A7 CU 23318 A7 CU23318 A7 CU 23318A7 CU 20030074 A CU20030074 A CU 20030074A CU 20030074 A CU20030074 A CU 20030074A CU 23318 A7 CU23318 A7 CU 23318A7
Authority
CU
Cuba
Prior art keywords
particle size
compositions
tizoxanida
nitazoxanida
farmacã0
Prior art date
Application number
CU20030074A
Other languages
English (en)
Inventor
Jean-Francois Rossignol
Original Assignee
Romark Lab Lc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/887,810 external-priority patent/US5856348A/en
Application filed by Romark Lab Lc filed Critical Romark Lab Lc
Publication of CU23318A7 publication Critical patent/CU23318A7/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica que contiene como agente activo por lo menos un compuesto seleccionado del grupo integrado por la fórmula I y la fórmula II. El agente activo tiene preferentemente la forma de partículas con un tamaÅ"o de partícula menor que 200 micrometros y un tamaÅ"o medio de partícula mayor que 10 micrometros. De manera preferente, las composiciones farmacéuticas están estabilizadas con por lo menos un ácido farmacéuticamente aceptable. Las composiciones farmacéuticas de la presente invención son útiles para el tratamiento de infecciones oportunistas en personas con el sistema inmune comprometido o suprimido, así como en el tratamiento de infecciones por tremátodos.</P>
CU20030074A 1997-05-07 2003-04-03 Composiciones farmacã0/00uticas de la tizoxanida y nitazoxanida CU23318A7 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/852,447 US5968961A (en) 1997-05-07 1997-05-07 Pharmaceutical compositions of tizoxanide and nitazoxanide
US08/887,810 US5856348A (en) 1994-09-08 1997-07-03 Method for treatment of trematodes with pharmaceutical compositions of tizoxanide and nitazoxanide

Publications (1)

Publication Number Publication Date
CU23318A7 true CU23318A7 (es) 2008-10-22

Family

ID=25313357

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20030074A CU23318A7 (es) 1997-05-07 2003-04-03 Composiciones farmacã0/00uticas de la tizoxanida y nitazoxanida

Country Status (12)

Country Link
US (2) US5968961A (es)
AR (1) AR008355A1 (es)
BG (1) BG65679B1 (es)
CO (1) CO4950538A1 (es)
CU (1) CU23318A7 (es)
ID (1) ID24828A (es)
LT (1) LT4751B (es)
PL (1) PL193556B1 (es)
PY (1) PY0000172A (es)
RO (1) RO122247B1 (es)
RS (2) RS49831B (es)
ZA (1) ZA983849B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7125568B2 (en) 2001-08-23 2006-10-24 Sung Michael T Lipophilic drug compositions
CA2467321A1 (en) * 2004-05-14 2005-11-14 Paul J. Santerre Polymeric coupling agents and pharmaceutically-active polymers made therefrom
UA90864C2 (en) 2004-09-09 2010-06-10 Ромарк Лебораториз, Л.К. Halogenated benzamide derivatives
AU2006235490A1 (en) * 2005-04-12 2006-10-19 Romark Laboratories, L.C. Methods for treating diseases through the function of molecular chaperones such as protein disulfide isomerases, pharmaceutical compositions comprising them, and screening methods for identifying therapeutic agents
CA2636527C (en) 2006-01-09 2016-05-17 Romark Laboratories, L.C. Viral hepatitis treatment
SI2395840T1 (sl) 2009-02-13 2020-08-31 Romark Laboratories, L.C. Farmacevtske formulacije nitazoksanida z nadzorovanim sproščanjem
NZ596538A (en) 2009-05-12 2014-04-30 Romark Lab Lc Haloalkyl heteroaryl benzamide compounds
CN108042535A (zh) 2009-06-26 2018-05-18 罗马克实验室有限公司 用于治疗流感的化合物和方法
CN107096032A (zh) 2011-05-16 2017-08-29 罗马克实验室有限公司 在有需要的对象中刺激免疫应答的方法
WO2013110975A1 (es) 2012-01-27 2013-08-01 Siegfried Rhein S.A. De C.V. Composición de nitazoxanida mejorada y proceso para prepararla
US20140306689A1 (en) 2013-04-10 2014-10-16 Texas Instruments, Incorporated High resolution current pulse analog measurement
MX2017006083A (es) 2014-11-11 2017-11-08 Romark Laboratories Lc Composicones y metodos de tratamiento con profarmacos de tizoxanida, un analogo o sal de la misma.
PT3436074T (pt) 2016-03-31 2020-08-21 Romark Laboratories Lc Compostos tiazolida para tratamento de infeções virais
JP6894923B2 (ja) 2016-04-11 2021-06-30 ジェンフィＧｅｎｆｉｔ 胆汁うっ滞性及び線維性の疾患の処置方法
WO2018195035A1 (en) 2017-04-18 2018-10-25 Romark Laboratories L.C. Inhibition of protein disulfide-isomerase a3
CN111971292B (zh) 2018-02-02 2024-12-13 波纹疗法公司 包含类固醇二聚体的玻璃制剂及其用途
WO2019241376A1 (en) 2018-06-14 2019-12-19 The Trustees Of Columbia University In The City Of New York Treatment of cognitive disorders using nitazoxanide (ntz), nitazoxanide (ntz) analogs, and metabolites thereof
WO2020154815A1 (en) 2019-02-01 2020-08-06 Ripple Therapeutics Corporation Crystalline forms of dexamethasone dimers and uses thereof
US12509469B2 (en) 2019-08-07 2025-12-30 Ripple Therapeutics Corporation Compositions and methods for the treatment of pain and dependence disorders
WO2021220061A2 (en) 2020-05-01 2021-11-04 Ripple Therapeutics Corporation Heterodimer compositions and methods for the treatment of ocular disorders
US20230303504A1 (en) 2020-07-20 2023-09-28 Romark Laboratories, L.C. Crystalline salts of tizoxanide and 2-hydroxy-n-(5-chloro-1,3-thiazol-2-yl)benzamide (rm-4848) with ethanolamine, morpholine, propanolamine, piperazine and n-methylpiperazine
MX2023002208A (es) 2020-08-24 2023-05-17 Romark Laboratories Lc Uso de tiazolidas contra los coronavirus.
WO2023058046A1 (en) 2021-10-05 2023-04-13 Council Of Scientific And Industrial Research An Indian Registered Body Incorporated Under The Regn. Of Soc. Act (Act Xxi Of 1860) An improved process for the preparation of nitazoxanide and intermediates thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1437800A (en) * 1973-08-08 1976-06-03 Phavic Sprl Derivatives of 2-benzamido-5-nitro-thiazoles
US4315018A (en) * 1978-12-07 1982-02-09 Rossignol Jean F Specific parasiticidal use of 2-benzamido-5-nitro-thiazole derivatives
US5496809A (en) * 1989-05-10 1996-03-05 Bristol-Myers Squibb Co Stable solutions of rebeccamycin analog
PL186504B1 (pl) 1994-04-13 2004-01-30 Romark Lab Pochodne benzamidowe i kompozycje farmaceutyczne zawierające te pochodne
US5578621A (en) * 1994-09-08 1996-11-26 Romark Lab Lc Benzamide derivatives
US5387598A (en) * 1994-04-13 1995-02-07 Rossignol; Jean-Francois Composition and galenic formulation suitable for combatting affections of the lower abdomen

Also Published As

Publication number Publication date
LT4751B (lt) 2001-01-25
RO122247B1 (ro) 2009-03-30
RS50046B (sr) 2008-11-28
RS20070379A (sr) 2008-06-05
RS49831B (sr) 2008-08-07
US6117894A (en) 2000-09-12
ID24828A (id) 2000-08-24
PL193556B1 (pl) 2007-02-28
LT99141A (lt) 2000-08-25
AR008355A1 (es) 2000-01-19
YU57199A (es) 2002-08-12
US5968961A (en) 1999-10-19
CO4950538A1 (es) 2000-09-01
ZA983849B (en) 1999-08-27
BG65679B1 (bg) 2009-06-30
PY0000172A (es) 2001-12-03

Similar Documents

Publication Publication Date Title
CU23318A7 (es) Composiciones farmacã0/00uticas de la tizoxanida y nitazoxanida
CO4810223A1 (es) Composiciones de champu estilizantes
BR0111126A (pt) Derivados de aminoácidos cìclicos úteis como agentes farmacêuticos
BR0212163A (pt) Composição para tratamento ou prevenção de infecção em plantas
MXPA03006999A (es) Composicion limpiadora espumante suave.
NZ513810A (en) Compositions and methods for improved delivery of hydrophobic therapeutic agents
DE60131088D1 (de) Gelierende wässrige pharmazeutische zusammensetzungen
BRPI0306993B8 (pt) polímero de polialquilenoglicol ativado; composição; e uso de um composto na produção de um medicamento para o tratamento de esclerose múltipla ou infecção viral suscetível
BR9808772A (pt) Composição de vacina multivalente com carreadora misturada
DK1318788T3 (da) Nanopartikulær fastdosissammensætninger
BRPI0311716A2 (pt) composição que contém um polímero catiônico com uma alta densidade de carga e um agente condicionador
BRPI0409185A (pt) formulações veterinárias anti-helmìnticas tópicas
BR0001468A (pt) ácidos dioxiciclopentil hidroxânicos
AR021624A1 (es) Composiciones para el lavado
CO5140079A1 (es) Composicion farmaceutica de liberacion sostenida y metodo para liberar un agente farmaceuticamente activo de liberacion sostenida y metodo para liberar un agente far- maceuticamente activo
ATE272628T1 (de) Substituierte gamma-phenyl-delta-lactone und deren analoge, und ihre verwendungen
EA200800950A1 (ru) Способы лечения и профилактики среднего отита с применением неионных поверхностно-активных веществ для облегчения трансмембранного введения лекарственного средства в среднее ухо
ECSP034915A (es) Formulacion farmaceutica de sabor enmascarado y procedimiento para su preparacion
ES2150404T3 (es) Composiciones farmaceuticas de tizoxanida y nitozoxanida.
PE20230514A1 (es) Composiciones farmaceuticas que comprenden acetato de 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il] e iones de sodio
BRPI0414139A (pt) métodos e composições para tratar infecções por herpes
BR0006301A (pt) Macrólidos antibacterianos e pró-cinéticos
DOP2000000091A (es) Composiciones farmaceuticas de la tizoxandia y la nitozoxandia
CU22990A3 (es) Composiciones farmacéuticas de la tizoxanida y la nitazoxadina
BRPI0410967A (pt) compostos, composições e seus usos para o tratamento de infecções por vìrus da famìlia flaviviridae